Evidence map›Paper›PMID 42708068›Full record

ReviewInternational journal of nanomedicine2026

Precision Nanodelivery Enables Spatiotemporal Control of NAD⁺ Metabolism in Ageing and Disease.

Zerong Pei, Xuemei Wang, Fengni Liang, Minyong Zhong, Qingxiang Jiang, Hui Li

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zerong PeiInstitute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, People's Republic of China.
Xuemei WangChina Department of Pharmacy, Tianjin First Central Hospital, Tianjin, People's Republic of China.
Fengni LiangDepartment of Pharmacy, Tianjin Medical University General Hospital Airport Site, Tianjin, People's Republic of China.
Minyong ZhongInstitute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, People's Republic of China.
Qingxiang JiangInstitute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, People's Republic of China.
Hui LiInstitute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Declining nicotinamide adenine dinucleotide (NAD⁺) represents a conserved metabolic hallmark of ageing, organ dysfunction and numerous acute and chronic disorders. NAD⁺ metabolism exhibits pronounced spatial, cell-type and subcellular compartmentalization in pathological tissues, orchestrating DNA repair, redox homeostasis, inflammatory cascades and mitochondrial energy metabolism. Such compartment heterogeneity accounts for the inconsistent therapeutic outcomes of systemic NAD⁺ precursor supplementation, which suffers from uneven tissue distribution and insufficient subcellular metabolite restoration. While conventional precursor replenishment lays a fundamental foundation for NAD⁺ intervention, its therapeutic potency is hampered by an inability to achieve localized, time-tunable metabolic modulation. Herein, we advocate a hierarchical precision nano-delivery framework to advance NAD⁺ therapeutics beyond passive systemic supplementation toward spatiotemporally programmable metabolic regulation. Nanodelivery platforms integrate tissue penetration, cellular uptake, organelle targeting and stimulus-triggered cargo release to overcome biological barriers and match NAD⁺ modulation to defined pathological disease windows. This Review systematically summarizes cutting-edge nanodelivery strategies for tissue-, cell- and organelle-specific delivery of NAD⁺, precursors and metabolic modulators across degenerative, inflammatory and metabolic illnesses. We further discuss key translational bottlenecks, including compartment-specific biomarkers, stratified safety evaluation, rational dosage regimen, scalable production and individualized patient stratification. We argue that the next generation of NAD⁺ therapeutics will not be defined by enhanced bulk supplementation alone, but by the capacity to orchestrate precise NAD⁺ manipulation across biological space and time.

Indexed as

AgingNADAnimalsHumansMetabolic DiseasesNADaging interventionhierarchical multiscale deliverymitochondrial NAD⁺ restorationNAD⁺ homeostasisprecision nanodeliverystimuli-responsive nanosystemssubcellular delivery

Identifiers

PMID42708068
PMCPMC13549304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.